RU2020117156A - Конъюгаты анти-cd40 антитела и лекарственного средства - Google Patents
Конъюгаты анти-cd40 антитела и лекарственного средства Download PDFInfo
- Publication number
- RU2020117156A RU2020117156A RU2020117156A RU2020117156A RU2020117156A RU 2020117156 A RU2020117156 A RU 2020117156A RU 2020117156 A RU2020117156 A RU 2020117156A RU 2020117156 A RU2020117156 A RU 2020117156A RU 2020117156 A RU2020117156 A RU 2020117156A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- drug conjugate
- conjugate
- compound
- paragraphs
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims 9
- 239000003814 drug Substances 0.000 title claims 9
- 239000000611 antibody drug conjugate Substances 0.000 claims 29
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000000562 conjugate Substances 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 208000002557 hidradenitis Diseases 0.000 claims 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593807P | 2017-12-01 | 2017-12-01 | |
| US62/593,807 | 2017-12-01 | ||
| US201762595045P | 2017-12-05 | 2017-12-05 | |
| US62/595,045 | 2017-12-05 | ||
| PCT/IB2018/059480 WO2019106608A1 (en) | 2017-12-01 | 2018-11-29 | Anti-cd40 antibody drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020117156A true RU2020117156A (ru) | 2022-01-04 |
Family
ID=66663861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020117156A RU2020117156A (ru) | 2017-12-01 | 2018-11-29 | Конъюгаты анти-cd40 антитела и лекарственного средства |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220265842A1 (enExample) |
| EP (1) | EP3716982A4 (enExample) |
| JP (1) | JP2021504430A (enExample) |
| KR (1) | KR20200095493A (enExample) |
| CN (1) | CN111465399A (enExample) |
| AU (1) | AU2018374633A1 (enExample) |
| BR (1) | BR112020010691A2 (enExample) |
| CA (1) | CA3081559A1 (enExample) |
| CL (1) | CL2020001442A1 (enExample) |
| CR (1) | CR20200285A (enExample) |
| DO (1) | DOP2020000119A (enExample) |
| EC (1) | ECSP20034868A (enExample) |
| IL (1) | IL274650A (enExample) |
| MX (1) | MX2020005465A (enExample) |
| PE (1) | PE20201464A1 (enExample) |
| PH (1) | PH12020550551A1 (enExample) |
| RU (1) | RU2020117156A (enExample) |
| SG (1) | SG11202004865SA (enExample) |
| WO (1) | WO2019106608A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021008305A (es) | 2019-01-11 | 2021-08-24 | Novartis Ag | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. |
| CA3207416A1 (en) * | 2021-02-04 | 2022-08-11 | Lingjian ZHU | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine |
| TW202304464A (zh) * | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 新穎糖皮質素受體激動劑 |
| BR112023016448A2 (pt) * | 2021-03-23 | 2023-10-24 | Lilly Co Eli | Agonistas de receptor de glucocorticoide |
| AR125079A1 (es) * | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
| CN117043172A (zh) * | 2021-03-23 | 2023-11-10 | 伊莱利利公司 | 糖皮质激素受体激动剂 |
| CN117580849A (zh) * | 2021-06-24 | 2024-02-20 | 江苏先声药业有限公司 | 甾体类化合物、其药物组合物及其应用 |
| EP4393937A1 (en) * | 2021-08-26 | 2024-07-03 | Duality Biologics (Suzhou) Co., Ltd. | Steroid compound and conjugate thereof |
| CN118201943A (zh) * | 2021-09-14 | 2024-06-14 | 映恩生物制药（苏州）有限公司 | 一种抗炎症的化合物及其用途 |
| WO2023245106A1 (en) * | 2022-06-16 | 2023-12-21 | Abbvie Biotherapeutics Inc. | Anti-cd19 antibody drug conjugates |
| CN120239705A (zh) | 2022-07-21 | 2025-07-01 | 萤火虫生物股份有限公司 | 糖皮质激素受体激动剂和其缀合物 |
| WO2024064779A1 (en) * | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
| WO2024140917A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海盛迪医药有限公司 | 抗cd40抗体药物偶联物、其制备方法及其医药用途 |
| CN120282801A (zh) * | 2022-12-28 | 2025-07-08 | 苏州盛迪亚生物医药有限公司 | 一种cd40结合分子的组合物及医药用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009069032A2 (en) * | 2007-11-30 | 2009-06-04 | Pfizer Limited | Novel glucocorticoid receptor agonists |
| WO2009085879A2 (en) * | 2007-12-21 | 2009-07-09 | Schering Corporation | C20-c21 substituted glucocorticoid receptor agonists |
| CN106928362B (zh) * | 2011-04-29 | 2021-10-26 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| US10550190B2 (en) * | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| HUE048284T2 (hu) * | 2015-05-29 | 2020-07-28 | Abbvie Inc | Anti-CD40 antitestek és alkalmazásuk |
| MY194619A (en) * | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
-
2018
- 2018-11-29 KR KR1020207017805A patent/KR20200095493A/ko active Pending
- 2018-11-29 SG SG11202004865SA patent/SG11202004865SA/en unknown
- 2018-11-29 CN CN201880077793.3A patent/CN111465399A/zh active Pending
- 2018-11-29 BR BR112020010691-7A patent/BR112020010691A2/pt not_active Application Discontinuation
- 2018-11-29 MX MX2020005465A patent/MX2020005465A/es unknown
- 2018-11-29 CA CA3081559A patent/CA3081559A1/en active Pending
- 2018-11-29 PE PE2020000592A patent/PE20201464A1/es unknown
- 2018-11-29 JP JP2020529611A patent/JP2021504430A/ja not_active Ceased
- 2018-11-29 US US16/768,616 patent/US20220265842A1/en not_active Abandoned
- 2018-11-29 EP EP18883152.3A patent/EP3716982A4/en not_active Withdrawn
- 2018-11-29 WO PCT/IB2018/059480 patent/WO2019106608A1/en not_active Ceased
- 2018-11-29 CR CR20200285A patent/CR20200285A/es unknown
- 2018-11-29 AU AU2018374633A patent/AU2018374633A1/en not_active Abandoned
- 2018-11-29 RU RU2020117156A patent/RU2020117156A/ru unknown
-
2020
- 2020-05-04 PH PH12020550551A patent/PH12020550551A1/en unknown
- 2020-05-13 IL IL274650A patent/IL274650A/en unknown
- 2020-05-29 CL CL2020001442A patent/CL2020001442A1/es unknown
- 2020-06-15 DO DO2020000119A patent/DOP2020000119A/es unknown
- 2020-06-29 EC ECSENADI202034868A patent/ECSP20034868A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021504430A (ja) | 2021-02-15 |
| DOP2020000119A (es) | 2020-08-31 |
| KR20200095493A (ko) | 2020-08-10 |
| EP3716982A1 (en) | 2020-10-07 |
| WO2019106608A1 (en) | 2019-06-06 |
| ECSP20034868A (es) | 2020-08-31 |
| PE20201464A1 (es) | 2020-12-17 |
| AU2018374633A1 (en) | 2020-05-21 |
| MX2020005465A (es) | 2020-09-07 |
| IL274650A (en) | 2020-06-30 |
| BR112020010691A2 (pt) | 2020-11-10 |
| CN111465399A (zh) | 2020-07-28 |
| CA3081559A1 (en) | 2019-06-06 |
| CL2020001442A1 (es) | 2020-09-11 |
| EP3716982A4 (en) | 2021-08-11 |
| PH12020550551A1 (en) | 2021-03-22 |
| SG11202004865SA (en) | 2020-06-29 |
| US20220265842A1 (en) | 2022-08-25 |
| CR20200285A (es) | 2020-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020117156A (ru) | Конъюгаты анти-cd40 антитела и лекарственного средства | |
| TWI839287B (zh) | 自行穩定之接合劑共軛物 | |
| RU2505603C2 (ru) | Антитело против рецептора il-6 | |
| ES2595638T3 (es) | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR | |
| ES2861582T3 (es) | Anticuerpos contra la proteína accesoria del recetor de interleucina humana (IL1RAP) y usos de los mismos | |
| JP2022044690A (ja) | 自己安定化リンカー結合体 | |
| CN118434765A (zh) | Bcma单克隆抗体和抗体-药物偶联物 | |
| IL266202B2 (en) | Antibody-conjugated cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide γ receptors | |
| PE20190355A1 (es) | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo | |
| JP2020079237A (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| JP2016500682A5 (enExample) | ||
| WO2014061277A1 (ja) | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| PE20240819A1 (es) | Anticuerpos anti-hla-g y uso de estos | |
| NZ601114A (en) | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies | |
| RU2015144186A (ru) | Очистка конъюгата антитело-лекарственное средство (аdс) | |
| CN113677364B (zh) | 包含抗191p4d12抗体药物偶联物的药物组合物及其使用方法 | |
| FI3773738T3 (fi) | Vasta-aine-lääkekonjugaatteja ja niiden käyttöjä syövän hoitamiseksi | |
| WO2023025248A1 (zh) | 一种甾体化合物及其缀合物 | |
| CN117597150A (zh) | 抗体依赖性细胞毒性的调节 | |
| AU2023231442A1 (en) | Antibody-drug conjugates and their uses | |
| JP2025091418A (ja) | 抗ｐｄ－１抗体および融合タンパク質 | |
| CA3113378C (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| AU2022208654A1 (en) | Compound or salt thereof, and antibody produced using same |